EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

HEV Infection in Beta-Thalassemia Patients

Despoina Papageorgiou, Anne-Lise de Lastic iD, Olga Tsachouridou iD, Simeon Metallidis, Karolina Akinosoglou iD

Pathogens · 2024

DOI: 10.3390/pathogens13121058 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pathogens, 2024. Verfasst von Despoina Papageorgiou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, University of Patras, Rio, 26504 Patras, Greece. Hauptthemen laut MEDLINE: Hepatitis E, beta-Thalassemia, Hepatitis E virus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thalassemia is an inherited hematological disorder characterized by a decrease in the synthesis of or absence of one or more globin chains. Hepatitis E virus (HEV) is a major cause of acute viral hepatitis, constituting a major global health burden and emerging as a critical public health concern. HEV infection is mainly transmitted via the fecal–oral route; however, parenteral transmission through blood components has been reported in both developing and developed countries. Although HEV infection is typically self-limiting, immunocompromised individuals, patients with chronic liver disease, and thalassemic patients are at a heightened risk of contracting the infection and may develop chronic hepatitis and life-threatening complications that require treatment. The reported prevalence rates of HEV in thalassemia patients vary significantly by country. Age, gender, residential area, and the cumulative amount of blood transfusions received have been identified as associated risk factors for HEV infection. In order to enhance blood safety and ensure the protection of vulnerable patient populations, such as thalassemia patients, several countries have introduced universal or targeted HEV screening policies in blood donations. Other preventive measures include vigilant monitoring of thalassemic patients and screening for anti-HEV antibodies. The aim of this review is to explore the prevalence, risk factors, clinical impact and management of HEV infection in patients with thalassemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis Ebeta-ThalassemiaHepatitis E virusHumansRisk FactorsPrevalenceBlood Transfusion

Stichwörter der Autor:innen

HEVbeta-thalassemiaclinical impacthepatitis Eprevalencepreventionrisk factorsthalassemia

Autor:innen und Institutionen

  • Medical School, University of Patras, Rio, 26504 Patras, Greece.
  • Laboratory of Immunohematology, Medical School, University of Patras, Rio, 26504 Patras, Greece.
  • Department of Internal Medicine and Infectious Diseases, AHEPA Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
  • Department of Internal Medicine and Infectious Diseases, University General Hospital of Patras, Rio, 26504 Patras, Greece.

ORCID-Profile: Anne-Lise de Lastic, Olga Tsachouridou, Karolina Akinosoglou

Zitieren

APA

Papageorgiou, D., de Lastic, A. L., Tsachouridou, O., Metallidis, S., & Akinosoglou, K. (2024). HEV Infection in Beta-Thalassemia Patients. Pathogens. https://doi.org/10.3390/pathogens13121058

Vancouver

Papageorgiou D, de Lastic AL, Tsachouridou O, Metallidis S, Akinosoglou K. HEV Infection in Beta-Thalassemia Patients. Pathogens. 2024. doi:10.3390/pathogens13121058

BibTeX
@article{Papageorgiou2024,
  author = {Papageorgiou, Despoina and de Lastic, Anne-Lise and Tsachouridou, Olga and Metallidis, Simeon and Akinosoglou, Karolina},
  title = {HEV Infection in Beta-Thalassemia Patients},
  journal = {Pathogens},
  year = {2024},
  doi = {10.3390/pathogens13121058}
}
Kostenlos starten →